Crossmark Global Holdings Inc. Has $11.69 Million Position in Elevance Health, Inc. (NYSE:ELV)

Crossmark Global Holdings Inc. trimmed its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 42.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,484 shares of the company's stock after selling 16,261 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Elevance Health were worth $11,691,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. American Trust raised its holdings in Elevance Health by 2.6% during the first quarter. American Trust now owns 775 shares of the company's stock valued at $402,000 after buying an additional 20 shares in the last quarter. Private Ocean LLC raised its stake in shares of Elevance Health by 6.7% in the second quarter. Private Ocean LLC now owns 348 shares of the company's stock valued at $189,000 after acquiring an additional 22 shares during the last quarter. Hurlow Wealth Management Group Inc. raised its position in Elevance Health by 1.9% in the 2nd quarter. Hurlow Wealth Management Group Inc. now owns 1,229 shares of the company's stock worth $666,000 after purchasing an additional 23 shares during the last quarter. Cypress Wealth Services LLC grew its holdings in Elevance Health by 3.5% during the 3rd quarter. Cypress Wealth Services LLC now owns 679 shares of the company's stock worth $353,000 after acquiring an additional 23 shares during the period. Finally, CVA Family Office LLC grew its holdings in shares of Elevance Health by 4.2% in the 2nd quarter. CVA Family Office LLC now owns 602 shares of the company's stock valued at $326,000 after buying an additional 24 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Elevance Health news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $432.14, for a total value of $3,205,182.38. Following the completion of the sale, the executive vice president now owns 8,423 shares in the company, valued at $3,639,915.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.35% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on ELV. Royal Bank of Canada cut their price target on shares of Elevance Health from $585.00 to $478.00 and set an "outperform" rating on the stock in a research report on Friday, October 18th. Mizuho reduced their price target on shares of Elevance Health from $585.00 to $505.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. Raymond James set a $485.00 price target on shares of Elevance Health in a report on Friday, October 18th. Stephens reiterated an "underperform" rating on shares of Elevance Health in a report on Friday, October 18th. Finally, Barclays cut their price target on Elevance Health from $622.00 to $501.00 and set an "overweight" rating on the stock in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $539.20.

Elevance Health Stock Up 0.7 %

NYSE:ELV traded up $2.77 during trading hours on Monday, hitting $425.39. The company's stock had a trading volume of 1,513,441 shares, compared to its average volume of 1,150,117. The stock has a fifty day moving average of $489.22 and a 200-day moving average of $517.72. The stock has a market capitalization of $98.66 billion, a P/E ratio of 15.51, a price-to-earnings-growth ratio of 1.26 and a beta of 0.85. Elevance Health, Inc. has a 52-week low of $397.98 and a 52-week high of $567.26. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.56.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings data on Thursday, October 17th. The company reported $8.37 earnings per share for the quarter, missing analysts' consensus estimates of $9.66 by ($1.29). The business had revenue of $44.72 billion during the quarter, compared to analysts' expectations of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. Elevance Health's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.99 EPS. On average, equities analysts forecast that Elevance Health, Inc. will post 32.96 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 20th. Stockholders of record on Thursday, December 5th will be issued a $1.63 dividend. This represents a $6.52 annualized dividend and a dividend yield of 1.53%. The ex-dividend date is Thursday, December 5th. Elevance Health's dividend payout ratio (DPR) is presently 23.77%.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.